68-5

88/120

(iGlarLixi) in Japanese people with type 2 diabetes: A subgroup and time-to-control analysis of the LixiLan JP phase 3 trials. Diabetes Obes Metab, 2020; 22 Suppl 4: 35-47, 10.1111/dom.14139.538 32) Funamizu T, Iwata H, Nishida Y, Miyosawa K, Doi S, Chikata Y, Shitara J, Endo H, Wada H, Naito R, Ogita M, Dohi T, Kasai T, Okazaki S, Isoda K, Miyauchi K, Daida H: Increased risk of cardiovascular mortality by strict glycemic control (pre-procedural HbA1c < 6.5%) in Japanese medically-treated diabetic patients following percutaneous coronary intervention: a 10-year follow-up study. Cardio‑vasc Diabetol, 2020; 19: 21, 10.1186/s12933-020-00996-8. 33) Uzawa H, Kohno D, Koga T, Sasaki T, Fukunaka A, Okuno T, Jo-Watanabe A, Kazuno S, Miyatsuka T, Kitamura T, Fujitani Y, Watada H, Saeki K, Yokomizo T: Leukotriene A(4) hydrolase deficiency protects mice from diet-induced obesity by increasing energy expenditure through neuroendocrine axis. FASEB J, 2020; 34: 13949-13958, 10.1096/fj. 202001148R. 34) Kuroda K, Matsumura Y, Ikemoto Y, Segawa T, Hashimoto T, Fukuda J, Nakagawa K, Uchida T, Ochiai A, Horimoto Y, Arakawa A, Nojiri S, Itakura A, Sugiyama R: Analysis of the risk factors and treatment for repeated implantation failure: OPtimization of Thyroid function, IMmunity, and Uterine Milieu (OPTIMUM) treatment strategy. Am J Reprod Immunol, 2020: e13376, 10.1111/aji. 13376. 35) Watada H, Yamauchi T, Yamamoto F, Tani‑guchi A, Yarush L, Heilmann C, Yasui A: Safety and tolerability of empagliflozin and linagliptin combination therapy in patients with type 2 diabetes mellitus: a pooled anal‑ysis of data from five randomized, controlled clinical trials. Expert Opin Drug Saf, 2020; 19: 1193-1202. 10.1080/14740338.2020.1782884. 36) Koga T, Sasaki F, Saeki K, Tsuchiya S, Okuno T, Ohba M, Ichiki T, Iwamoto S, Uzawa H, Kitajima K, Meno C, Nakamura E, Tada N, Fukui Y, Kikuta J, Ishii M, Sugimoto Y, Nakao M, Yokomizo T: Expression of leukotriene B(4) receptor 1 defines functionally distinct DCs that control allergic skin inflammation. Cell Mol Immunol, 2020. 10.1038/s41423-020-00559-7. 37) Khunti K, Gomes M.B, Kosiborod M, Nico‑lucci A, Pocock S, Rathmann W, Shestakova M.V, Shimomura I, Watada H, Chen H, Cid- Ruzafa J, Fenici P, Hammar N, Tang F, Ji L: Metformin discontinuation in patients begin‑ning second-line glucose-lowering therapy: results the global observational DISCOVER study programme. BMJ Open, 2020; 10: e034613, 10.1136/bmjopen-2019-034613. 38) Yabe D, Higashiyama H, Kadowaki T, Origasa H, Shimomura I, Watada H, Tobe K, Iglay K, Tokita S, Seino Y: Real-world Observational Study on Patient Outcomes in Diabetes (RESPOND): study design and baseline char‑acteristics of patients with type 2 diabetes newly initiating oral antidiabetic drug mono‑therapy in Japan. BMJ Open Diabetes Res Care, 2020; 8. 10.1136/bmjdrc-2020-001361. 39) Yamauchi T, Kamiya H, Utsunomiya K, Watada H, Kawanami D, Sato J, Kitada M, Koya D, Harada N, Shide K, Joo E, Suzuki R, Bouchi R, Ohta Y, Kondo T: Medical nutrition therapy and dietary counseling for patients with diabetes-energy, carbohydrates, protein intake and dietary counseling. Diabetol Int, 2020; 11: 224-239, 10.1007/s13340-020-00437-7. 40) Katakami N, Mita T, Yoshii H, Shiraiwa T, Yasuda T, Okada Y, Torimoto K, Umayahara Y, Kaneto H, Osonoi T, Yamamoto T, Kurib‑ayashi N, Maeda K, Yokoyama H, Kosugi K, Ohtoshi K, Hayashi I, Sumitani S, Tsugawa M, Ryomoto K, Taki H, Nakamura T, Kawashima S, Sato Y, Watada H, Shimomura I, investigators U.s: Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospec‑tive, randomized, open-label, parallel-group comparative study. Cardiovasc Diabetol, 2020; 19: 110. 10.1186/s12933-020-01079-4. 41) Tsunemi A, Sato J, Kurita M, Wakabayashi Y, Waseda N, Koshibu M, Shinohara M, Ozaki A, Nakamura H, Hirano N, Ikeda F, Satoh H, Watada H: Effect of real-life insulin pump with predictive low-glucose management use for 3 months: Analysis of the patients from